Health & Fitness
Fri, March 1, 2013Thu, February 28, 2013Wed, February 27, 2013Tue, February 26, 2013Mon, February 25, 2013Sun, February 24, 2013Sat, February 23, 2013Fri, February 22, 2013Thu, February 21, 2013Wed, February 20, 2013Tue, February 19, 2013Mon, February 18, 2013Sun, February 17, 2013Fri, February 15, 2013Thu, February 14, 2013Wed, February 13, 2013Tue, February 12, 2013Mon, February 11, 2013Sun, February 10, 2013Fri, February 8, 2013Thu, February 7, 2013Orphan Drug Catalyst Pushing DARA Shares Toward Possible Technical Break-Out
Published in Health and Fitness on Tuesday, February 19th 2013 at 5:16 GMT by Market Wire
February 19, 2013 08:06 ET
Orphan Drug Catalyst Pushing DARA Shares Toward Possible Technical Break-Out
LOS ANGELES, CA--(Marketwire - Feb 19, 2013) - DARABiosciences (
KRN5500 is a novel, spicamycin-derived, non-opioid-non-narcotic intravenous pain therapeutic with promising clinical trial results in patients with chemotherapy-induced peripheral neuropathy (CIPN).
More than 70% of patients treated with taxane-class or platinum-class chemotherapeutic agents; at least 25% of those treated with vinca-class agents; and significant numbers of those treated with Thalomid®, Revlimid®, Velcade®, and a variety of other cancer drugs experience CIPN, which can be disabling and adversely affect quality of life.
There is presently no FDA-approved drug for CIPN.
In October, 2011, the U.S. FDA granted KRN-5500 Fast Track designation for CIPN, an indication with a market potential estimated at $2.5B.
Summary of Phase 2a clinical trial results:
- "A Spicamycin Derivative (KRN5500) Provides Neuropathic Pain Relief in Patients with Advanced Cancer: A Placebo-Controlled, Proof-of-Concept Trial"; Journal of Pain and Symptom Management [ http://digitalreprints.elsevier.com/issue/47166 ].
- Patients had failed on at least two previous pain therapeutics
- KRN5500 met primary endpoints: reduction of pain and safety
- Significantly more effective than placebo (p=0.03)
- Transient and manageable GI side effects
The stock is trading in a manner that hints at positive news concerning the Orphan Drug status application.
For example, the [ stock chart for DARA ] is forming a cup and handle breakout pattern with resistance at $1.20. Once past this level, the near term price target indicates a test of the prior high of $1.38. Measuring the cup and handle break indicates a move over $2 in the coming months.
Disclosure: Author Scott Matusow is Long DARA.
The full version of this report complete with a technical analysis chart can be found here:
[ http://www.biomedreports.com/20130219123429/orphan-drug-catalyst-on-tap-for-dara.html ]
[ Healthcare investors ] and [ Biotech traders ] interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to: [ http://biomedreports.com/fdacal.html ]
Follow Us
News developments and live healthcare sector updates are available constantly via twitter at: [ http://twitter.com/BioMedReports ]
About BioMedReports.Com
BioMedReports is a news and research portal covering[ financial biotech news ] for the entire [ Healthcare Sector ] of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. BioMedReports sells a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release are available at BioMedReports.Com
